Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614996 | 1.00 | MEN1 (0.46) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL10705365 | 0.92 | KMT2A (0.52) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL7605558 | 0.92 | KMT2A (0.52) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL8772693 | 0.92 | KMT2A (0.52) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL13736496 | 0.92 | KMT2A (0.52) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL1516089 | 0.88 | KMT2A (0.50) | MEN1KMT2AEPHX2LMNA | |
| SCHEMBL9464941 | 0.86 | MGLL (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL27160928 | 0.86 | MGLL (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL9464928 | 0.86 | MGLL (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL23925493 | 0.86 | KMT2A (0.52) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2020-01-30 | — | — | US | disclosed |
| WO-2017156164-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | MEN1 3401/4885KMT2A 3465/4885EPHX2 506/4885 |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | MEN1 3401/4885KMT2A 3465/4885EPHX2 506/4885 |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | GPR55, GPR65, GPR35 | MEN1 3401/4885KMT2A 3465/4885EPHX2 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.